Sogroya^® is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD) and for the treatment of pediatric patients aged 2.5 years and older with: growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature born Small for Gestational Age (SGA) and with no catch-up growth by 2 years of age, growth failure associated with Noonan Syndrome (NS), and Idiopathic Short Stature (ISS). Please see full indications.

Chart based on Kapoor RR, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child. 2008;93(2):147-148.

Patients who missed >2 injections per week had a 41% lower median HV than those who missed none^1,a,b

Factors associated with lower adherence to therapy were a longer duration on GH therapy, lack of choice over GH device, and short duration (<4 weeks) of GH prescriptions

^aUK study of 75 children with GHD who received GH therapy and attended a regional pediatric endocrine clinic from 1999 to 2003. 58 general practitioners (GPs) who issued GH prescriptions responded to a mailed questionnaire (66 GPs were contacted; 88% response rate) with the number of issued prescriptions and the total GH dose (or number of vials/cartridges) issued with each prescription during 3 specific 12-month periods (1999-2000, 2000-2001, and 2002-2003). Data on 11 patients were obtained from an outreach clinic where GH prescriptions were provided directly by a designated local consultant pediatrician. Adherence was assessed in each child by comparing total expected GH usage as documented in clinic records and letters to the total amount of GH prescribed by GPs during a 12-month period.¹

^bAdjusted for age and duration of GH therapy.¹

GHD=growth hormone deficiency; HV=height velocity; GH=growth hormone.

In a systematic literature review and meta-analysis of medication adherence with once-weekly vs once-daily therapy,

Once-weekly treatment adherence was ~2X better than once-daily treatment^2,c

^cMeta-analysis of observational studies which were conducted in patients with osteoporosis.²

According to an LAGH Consensus Statement for pediatric GHD patients, developed independently by a panel of renowned pediatric endocrinology experts³:

LAGH formulations offer a potential advantage over daily GH injections for children with GH deficiency in terms of reduced injection frequency and treatment burden; this may also be associated with improved adherence and treatment outcomes over time. However, long-term data is needed

Parents/caregivers have shown a strong preference for the reduced frequency of LAGH preparations over daily GH formulations

It is likely that most if not all children could be considered for a weekly administration regimen, particularly children or their caregivers who experience challenges with injections, as well as those at increased risk of non-adherence, frequent travel schedules, and split households

Consider if the flexibility of a once-weekly GH treatment option may impact your patient’s persistence and treatment experience

GH=growth hormone; GHD=growth hormone deficiency; LAGH=long-acting growth hormone.

Growth Hormone Deficiency (GHD) Other Pediatric Growth-Related Conditions

Growth Hormone Deficiency (GHD)

Patients with GHD continue to face challenges with daily injections⁴

Non-adherence to daily GH treatment is common and has been addressed in many studies^5,6

Repeated injections are one of the main causes of non-adherence in pediatric-aged patients⁷

Children, adolescents, and their caregivers may struggle with continual daily injections over the long term⁴

Missed daily injections may impact growth outcomes⁸

GHD=growth hormone deficiency; GH=growth hormone

Missing

per week of daily
GH treatment

results in missing up to

of treatment
in a year

which equates to missing

of doses over a 7-year
treatment period

Adult GHD (AGHD) is most often acquired from^9,10:

A pituitary tumor^9,10

Including treatment with surgery and/or radiation¹⁰

Trauma to the brain⁹

Other patient subpopulations include subarachnoid hemorrhage, ischemic stroke, and infections in the central nervous system⁹

AGHD may also be idiopathic or due to other organic causes.^9,10

Reduced energy levels

Reduced muscle strength

Osteoporosis

Lipid abnormalities

Increased total body fat

Insulin resistance

Impaired cardiac function

Reduced energy levels

Reduced muscle strength

Osteoporosis

Lipid abnormalities

Increased total body fat

Insulin resistance

Impaired cardiac function

Per the American Association of Clinical Endocrinologists (AACE), identifying adult patients with GHD includes assessing¹⁰:

PATIENTS WITH CLINICAL FEATURES SUGGESTIVE OF AGHD

eg, patients with organic hypothalamic-pituitary disease and low-serum IGF-1 levels

BIOCHEMICALLY PROVEN
EVIDENCE OF AGHD

eg, GH stimulation testing

With diagnosis confirmed, AACE recommends treating AGHD with growth hormone therapy¹⁰
While once-daily GH treatment is considered the standard of care, according to GRS consensus, a once-weekly GH option may also help⁴

AGHD=adult growth hormone deficiency; GH=growth hormone; GHD=growth hormone deficiency; GRS=Growth Hormone Research Society; IGF-1=insulin-like growth factor-1.

Other Pediatric Growth-Related Conditions

Treatment burden in ISS:

Diagnosis and treatment can be delayed, potentially reducing the treatment window^15,16

Average treatment duration is 4 to 7 years¹⁴

Treatment drop-out due to poor  
adherence is common¹⁵

GH=growth hormone; ISS=Idiopathic Short Stature.

Treatment burden in SGA:

In a cohort from an observational French registry study:

≈20% of patients (n=58/291) with SGA prematurely stopped GH treatment before reaching a normalized height^17,d

Reasons for premature discontinuation included safety concerns, poor adherence, satisfaction with attained height, and patient, parent, or physician decision¹⁷

SGA can be associated with multiple comorbidities, which may increase treatment burden^19,20

Parents of newborns born SGA may experience higher levels of psychological burden compared to those born normal for gestational age.²¹

^dBased on an observational, multicenter, non-interventional French registry study that assessed the effectiveness and safety of daily GH in 1408 French children born SGA from 2005 to 2010. A cohort of 291 children were randomly selected for every fifth patient in the main study population to be followed for up to 6 months after the first visit and then annually until achieving final adult height or study termination. Final adult height was defined as height velocity <2 cm/year or bone age >14 years for girls and >16 years for boys. Normalized height was defined as height SDS >-2 from the reference population.

GH=growth hormone; SDS=standard deviation score; SGA=Small for Gestational Age.

Treatment burden in NS:

NS is a lifelong, multisystem condition with diverse complications and comorbidities that requires multidisciplinary care^24,25

Late diagnosis may limit their GH treatment window²²

Data suggest poor adherence to daily GH therapy may lead to a reduced height velocity for patients with NS²³

GH=growth hormone; NS=Noonan Syndrome.

Missing 1 day per week of daily GH treatment is equivalent to missing 52 days of treatment in a year. If the treatment period is 7 years, this equates to skipping a full year of treatment.

Take a look at the features of the Sogroya^® pen.

Discover the science behind Sogroya^®.

Show More Show Less

Important Safety Information for Sogroya^®

Contraindications

Sogroya^® is contraindicated in patients with:

acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure because of the risk of increased mortality with use of Sogroya^®
hypersensitivity to Sogroya^® or any of its excipients. Systemic hypersensitivity reactions have been reported postmarketing with somatropin
pediatric patients with closed epiphyses
active malignancy
active proliferative or severe non-proliferative diabetic retinopathy
pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to risk of sudden death

Warnings & Precautions

Increased Mortality in Patients with Acute Critical Illness: Increased mortality has been reported after treatment with somatropin in patients with acute critical illness due to complications following open-heart surgery, abdominal surgery, multiple accidental trauma, and in patients with acute respiratory failure
Severe Hypersensitivity: Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported postmarketing with use of somatropin. Inform patients and/or caregivers that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs
Increased Risk of Neoplasms: There is an increased risk of malignancy progression with somatropin in patients with active malignancy. Any preexisting malignancy should be inactive, and its treatment complete prior to instituting Sogroya^®. In childhood cancer survivors treated with radiation to the brain/head for their first neoplasm who developed subsequent GHD and were treated with somatropin, an increased risk of a second neoplasm has been reported. Monitor patients with a history of GHD secondary to an intracranial neoplasm for progression or recurrence of the tumor. Children with certain rare genetic causes of short stature have an increased risk of developing malignancies and should be carefully monitored for development of neoplasms. Monitor patients for increased growth or potential malignant changes of preexisting nevi. Advise patients/caregivers to report changes in the appearance of preexisting nevi
Glucose Intolerance and Diabetes Mellitus: Treatment with somatropin may decrease insulin sensitivity, particularly at higher doses. New onset type 2 diabetes has been reported. Monitor glucose levels in all patients, especially in those with existing diabetes mellitus or with risk factors for diabetes mellitus, such as obesity, Turner syndrome, or a family history of diabetes mellitus. The doses of antidiabetic agents may require adjustment when Sogroya^® is initiated
Intracranial Hypertension: Has been reported usually within 8 weeks of treatment initiation. Perform fundoscopic examination prior to initiation of treatment and periodically thereafter. If papilledema is identified, evaluate the etiology, and treat the underlying cause before initiating Sogroya^®. If papilledema is observed, stop treatment. If intracranial hypertension is confirmed, Sogroya^® can be restarted at a lower dose after intracranial hypertension signs and symptoms have resolved
Fluid Retention: Was observed during Sogroya^® therapy. Clinical manifestations of fluid retention (e.g. edema and nerve compression syndromes, including carpal tunnel syndrome/paresthesia) are usually transient and dose dependent
Hypoadrenalism: Patients receiving somatropin therapy who have or are at risk for corticotropin deficiency may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of Sogroya^®. Monitor patients with known hypoadrenalism for reduced serum cortisol levels and/or need for glucocorticoid dose increases
Hypothyroidism: Undiagnosed/untreated hypothyroidism may prevent an optimal response to Sogroya^®. Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of Sogroya^®
Slipped Capital Femoral Epiphysis in Pediatric Patients: Slipped capital femoral epiphysis may occur more frequently in patients undergoing rapid growth. Slipped capital femoral epiphysis may lead to osteonecrosis. Cases of slipped capital femoral epiphysis with or without osteonecrosis have been reported in pediatric patients with short stature receiving somatropin. Evaluate pediatric patients receiving Sogroya® with the onset of a limp or complaints of persistent hip or knee pain for slipped capital femoral epiphysis and osteonecrosis and manage accordingly
Progression of Preexisting Scoliosis in Pediatric Patients: Monitor patients with a history of scoliosis for disease progression
Pancreatitis: Cases of pancreatitis have been reported in patients receiving somatropin. The risk may be greater in pediatric patients compared to adults. Consider pancreatitis in patients with persistent severe abdominal pain
Lipohypertrophy/Lipoatrophy: May occur if Sogroya^® is administered at the same site over a long period of time. Rotate injection sites to reduce this risk
Sudden Death in Pediatric Patients with Prader-Willi Syndrome: There have been reports of fatalities after initiating therapy with somatropin in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk than females. Sogroya^® is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome
Laboratory Tests: Serum levels of inorganic phosphorus and alkaline phosphatase have increased after Sogroya^® therapy. Serum levels of parathyroid hormone may increase with somatropin treatment

Adverse Reactions

Common adverse reactions in pediatric patients treated with Sogroya^® include: cough, diarrhea, ear infection, headache, injection site reaction, nasopharyngitis, pain in extremity, pyrexia, respiratory tract infection, and vomiting
Adult patients with GHD: Adverse reactions reported in >2% of patients are: back pain, arthralgia, dyspepsia, sleep disorder, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, blood creatine phosphokinase increase, weight increase, anemia

Drug Interactions

Glucocorticoids: Patients treated with glucocorticoid for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of Sogroya^®
Cytochrome P450-Metabolized Drugs: Sogroya^® may alter the clearance. Monitor carefully if used with Sogroya^®
Oral Estrogen: Patients receiving oral estrogen replacement may require higher Sogroya^® dosages
Insulin and/or Other Antihyperglycemic Agents: Dose adjustment of insulin and/or antihyperglycemic agent may be required for patients with diabetes mellitus

Please click here for Sogroya^® Prescribing Information.

Indications and Usage

Sogroya^® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg is indicated for the:

treatment of pediatric patients aged 2.5 years and older with:
- Growth failure due to inadequate secretion of endogenous growth hormone (GH)
- Short stature born Small for Gestational Age (SGA) and with no catch-up growth by 2 years of age
- Growth failure associated with Noonan Syndrome (NS)
- Idiopathic Short Stature (ISS)
replacement of endogenous GH in adults with growth hormone deficiency (GHD)

Indications and Usage

Sogroya^® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg is indicated for the:

treatment of pediatric patients aged 2.5 years and older with:
- Growth failure due to inadequate secretion of endogenous growth hormone (GH)
- Short stature born Small for Gestational Age (SGA) and with no catch-up growth by 2 years of age
- Growth failure associated with Noonan Syndrome (NS)
- Idiopathic Short Stature (ISS)
replacement of endogenous GH in adults with growth hormone deficiency (GHD)

Important Safety Information for Sogroya^®

Contraindications

Sogroya^® is contraindicated in patients with:

acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure because of the risk of increased mortality with use of Sogroya^®
hypersensitivity to Sogroya^® or any of its excipients. Systemic hypersensitivity reactions have been reported postmarketing with somatropin
pediatric patients with closed epiphyses
active malignancy
active proliferative or severe non-proliferative diabetic retinopathy
pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to risk of sudden death

Warnings & Precautions

Increased Mortality in Patients with Acute Critical Illness: Increased mortality has been reported after treatment with somatropin in patients with acute critical illness due to complications following open-heart surgery, abdominal surgery, multiple accidental trauma, and in patients with acute respiratory failure
Severe Hypersensitivity: Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported postmarketing with use of somatropin. Inform patients and/or caregivers that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs
Increased Risk of Neoplasms: There is an increased risk of malignancy progression with somatropin in patients with active malignancy. Any preexisting malignancy should be inactive, and its treatment complete prior to instituting Sogroya^®. In childhood cancer survivors treated with radiation to the brain/head for their first neoplasm who developed subsequent GHD and were treated with somatropin, an increased risk of a second neoplasm has been reported. Monitor patients with a history of GHD secondary to an intracranial neoplasm for progression or recurrence of the tumor. Children with certain rare genetic causes of short stature have an increased risk of developing malignancies and should be carefully monitored for development of neoplasms. Monitor patients for increased growth or potential malignant changes of preexisting nevi. Advise patients/caregivers to report changes in the appearance of preexisting nevi
Glucose Intolerance and Diabetes Mellitus: Treatment with somatropin may decrease insulin sensitivity, particularly at higher doses. New onset type 2 diabetes has been reported. Monitor glucose levels in all patients, especially in those with existing diabetes mellitus or with risk factors for diabetes mellitus, such as obesity, Turner syndrome, or a family history of diabetes mellitus. The doses of antidiabetic agents may require adjustment when Sogroya^® is initiated
Intracranial Hypertension: Has been reported usually within 8 weeks of treatment initiation. Perform fundoscopic examination prior to initiation of treatment and periodically thereafter. If papilledema is identified, evaluate the etiology, and treat the underlying cause before initiating Sogroya^®. If papilledema is observed, stop treatment. If intracranial hypertension is confirmed, Sogroya^® can be restarted at a lower dose after intracranial hypertension signs and symptoms have resolved
Fluid Retention: Was observed during Sogroya^® therapy. Clinical manifestations of fluid retention (e.g. edema and nerve compression syndromes, including carpal tunnel syndrome/paresthesia) are usually transient and dose dependent
Hypoadrenalism: Patients receiving somatropin therapy who have or are at risk for corticotropin deficiency may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of Sogroya^®. Monitor patients with known hypoadrenalism for reduced serum cortisol levels and/or need for glucocorticoid dose increases
Hypothyroidism: Undiagnosed/untreated hypothyroidism may prevent an optimal response to Sogroya^®. Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of Sogroya^®
Slipped Capital Femoral Epiphysis in Pediatric Patients: Slipped capital femoral epiphysis may occur more frequently in patients undergoing rapid growth. Slipped capital femoral epiphysis may lead to osteonecrosis. Cases of slipped capital femoral epiphysis with or without osteonecrosis have been reported in pediatric patients with short stature receiving somatropin. Evaluate pediatric patients receiving Sogroya® with the onset of a limp or complaints of persistent hip or knee pain for slipped capital femoral epiphysis and osteonecrosis and manage accordingly
Progression of Preexisting Scoliosis in Pediatric Patients: Monitor patients with a history of scoliosis for disease progression
Pancreatitis: Cases of pancreatitis have been reported in patients receiving somatropin. The risk may be greater in pediatric patients compared to adults. Consider pancreatitis in patients with persistent severe abdominal pain
Lipohypertrophy/Lipoatrophy: May occur if Sogroya^® is administered at the same site over a long period of time. Rotate injection sites to reduce this risk
Sudden Death in Pediatric Patients with Prader-Willi Syndrome: There have been reports of fatalities after initiating therapy with somatropin in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk than females. Sogroya^® is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome
Laboratory Tests: Serum levels of inorganic phosphorus and alkaline phosphatase have increased after Sogroya^® therapy. Serum levels of parathyroid hormone may increase with somatropin treatment

Adverse Reactions

Common adverse reactions in pediatric patients treated with Sogroya^® include: cough, diarrhea, ear infection, headache, injection site reaction, nasopharyngitis, pain in extremity, pyrexia, respiratory tract infection, and vomiting
Adult patients with GHD: Adverse reactions reported in >2% of patients are: back pain, arthralgia, dyspepsia, sleep disorder, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, blood creatine phosphokinase increase, weight increase, anemia

Drug Interactions

Glucocorticoids: Patients treated with glucocorticoid for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of Sogroya^®
Cytochrome P450-Metabolized Drugs: Sogroya^® may alter the clearance. Monitor carefully if used with Sogroya^®
Oral Estrogen: Patients receiving oral estrogen replacement may require higher Sogroya^® dosages
Insulin and/or Other Antihyperglycemic Agents: Dose adjustment of insulin and/or antihyperglycemic agent may be required for patients with diabetes mellitus

Please click here for Sogroya^® Prescribing Information.

Show More Show Less

Indications and Usage

Sogroya^® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg is indicated for the:

treatment of pediatric patients aged 2.5 years and older with:
- Growth failure due to inadequate secretion of endogenous growth hormone (GH)
- Short stature born Small for Gestational Age (SGA) and with no catch-up growth by 2 years of age
- Growth failure associated with Noonan Syndrome (NS)
- Idiopathic Short Stature (ISS)
replacement of endogenous GH in adults with growth hormone deficiency (GHD)

Important Safety Information for Sogroya^®

Contraindications

Sogroya^® is contraindicated in patients with:

acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure because of the risk of increased mortality with use of Sogroya^®
hypersensitivity to Sogroya^® or any of its excipients. Systemic hypersensitivity reactions have been reported postmarketing with somatropin
pediatric patients with closed epiphyses
active malignancy
active proliferative or severe non-proliferative diabetic retinopathy
pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to risk of sudden death

Important Safety Information for Sogroya^®

Contraindications

Sogroya^® is contraindicated in patients with:

acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure because of the risk of increased mortality with use of Sogroya^®
hypersensitivity to Sogroya^® or any of its excipients. Systemic hypersensitivity reactions have been reported postmarketing with somatropin
pediatric patients with closed epiphyses
active malignancy
active proliferative or severe non-proliferative diabetic retinopathy
pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to risk of sudden death

Warnings & Precautions

Increased Mortality in Patients with Acute Critical Illness: Increased mortality has been reported after treatment with somatropin in patients with acute critical illness due to complications following open-heart surgery, abdominal surgery, multiple accidental trauma, and in patients with acute respiratory failure
Severe Hypersensitivity: Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported postmarketing with use of somatropin. Inform patients and/or caregivers that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs
Increased Risk of Neoplasms: There is an increased risk of malignancy progression with somatropin in patients with active malignancy. Any preexisting malignancy should be inactive, and its treatment complete prior to instituting Sogroya^®. In childhood cancer survivors treated with radiation to the brain/head for their first neoplasm who developed subsequent GHD and were treated with somatropin, an increased risk of a second neoplasm has been reported. Monitor patients with a history of GHD secondary to an intracranial neoplasm for progression or recurrence of the tumor. Children with certain rare genetic causes of short stature have an increased risk of developing malignancies and should be carefully monitored for development of neoplasms. Monitor patients for increased growth or potential malignant changes of preexisting nevi. Advise patients/caregivers to report changes in the appearance of preexisting nevi
Glucose Intolerance and Diabetes Mellitus: Treatment with somatropin may decrease insulin sensitivity, particularly at higher doses. New onset type 2 diabetes has been reported. Monitor glucose levels in all patients, especially in those with existing diabetes mellitus or with risk factors for diabetes mellitus, such as obesity, Turner syndrome, or a family history of diabetes mellitus. The doses of antidiabetic agents may require adjustment when Sogroya^® is initiated
Intracranial Hypertension: Has been reported usually within 8 weeks of treatment initiation. Perform fundoscopic examination prior to initiation of treatment and periodically thereafter. If papilledema is identified, evaluate the etiology, and treat the underlying cause before initiating Sogroya^®. If papilledema is observed, stop treatment. If intracranial hypertension is confirmed, Sogroya^® can be restarted at a lower dose after intracranial hypertension signs and symptoms have resolved
Fluid Retention: Was observed during Sogroya^® therapy. Clinical manifestations of fluid retention (e.g. edema and nerve compression syndromes, including carpal tunnel syndrome/paresthesia) are usually transient and dose dependent
Hypoadrenalism: Patients receiving somatropin therapy who have or are at risk for corticotropin deficiency may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of Sogroya^®. Monitor patients with known hypoadrenalism for reduced serum cortisol levels and/or need for glucocorticoid dose increases
Hypothyroidism: Undiagnosed/untreated hypothyroidism may prevent an optimal response to Sogroya^®. Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of Sogroya^®
Slipped Capital Femoral Epiphysis in Pediatric Patients: Slipped capital femoral epiphysis may occur more frequently in patients undergoing rapid growth. Slipped capital femoral epiphysis may lead to osteonecrosis. Cases of slipped capital femoral epiphysis with or without osteonecrosis have been reported in pediatric patients with short stature receiving somatropin. Evaluate pediatric patients receiving Sogroya® with the onset of a limp or complaints of persistent hip or knee pain for slipped capital femoral epiphysis and osteonecrosis and manage accordingly
Progression of Preexisting Scoliosis in Pediatric Patients: Monitor patients with a history of scoliosis for disease progression
Pancreatitis: Cases of pancreatitis have been reported in patients receiving somatropin. The risk may be greater in pediatric patients compared to adults. Consider pancreatitis in patients with persistent severe abdominal pain
Lipohypertrophy/Lipoatrophy: May occur if Sogroya^® is administered at the same site over a long period of time. Rotate injection sites to reduce this risk
Sudden Death in Pediatric Patients with Prader-Willi Syndrome: There have been reports of fatalities after initiating therapy with somatropin in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk than females. Sogroya^® is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome
Laboratory Tests: Serum levels of inorganic phosphorus and alkaline phosphatase have increased after Sogroya^® therapy. Serum levels of parathyroid hormone may increase with somatropin treatment

Adverse Reactions

Common adverse reactions in pediatric patients treated with Sogroya^® include: cough, diarrhea, ear infection, headache, injection site reaction, nasopharyngitis, pain in extremity, pyrexia, respiratory tract infection, and vomiting
Adult patients with GHD: Adverse reactions reported in >2% of patients are: back pain, arthralgia, dyspepsia, sleep disorder, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, blood creatine phosphokinase increase, weight increase, anemia

Drug Interactions

Glucocorticoids: Patients treated with glucocorticoid for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of Sogroya^®
Cytochrome P450-Metabolized Drugs: Sogroya^® may alter the clearance. Monitor carefully if used with Sogroya^®
Oral Estrogen: Patients receiving oral estrogen replacement may require higher Sogroya^® dosages
Insulin and/or Other Antihyperglycemic Agents: Dose adjustment of insulin and/or antihyperglycemic agent may be required for patients with diabetes mellitus

Please click here for Sogroya^® Prescribing Information.

Important Safety Information for Sogroya^®

Contraindications

Sogroya^® is contraindicated in patients with:

acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure because of the risk of increased mortality with use of Sogroya^®
hypersensitivity to Sogroya^® or any of its excipients. Systemic hypersensitivity reactions have been reported postmarketing with somatropin
pediatric patients with closed epiphyses
active malignancy
active proliferative or severe non-proliferative diabetic retinopathy
pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to risk of sudden death

Warnings & Precautions

Increased Mortality in Patients with Acute Critical Illness: Increased mortality has been reported after treatment with somatropin in patients with acute critical illness due to complications following open-heart surgery, abdominal surgery, multiple accidental trauma, and in patients with acute respiratory failure
Severe Hypersensitivity: Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported postmarketing with use of somatropin. Inform patients and/or caregivers that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs
Increased Risk of Neoplasms: There is an increased risk of malignancy progression with somatropin in patients with active malignancy. Any preexisting malignancy should be inactive, and its treatment complete prior to instituting Sogroya^®. In childhood cancer survivors treated with radiation to the brain/head for their first neoplasm who developed subsequent GHD and were treated with somatropin, an increased risk of a second neoplasm has been reported. Monitor patients with a history of GHD secondary to an intracranial neoplasm for progression or recurrence of the tumor. Children with certain rare genetic causes of short stature have an increased risk of developing malignancies and should be carefully monitored for development of neoplasms. Monitor patients for increased growth or potential malignant changes of preexisting nevi. Advise patients/caregivers to report changes in the appearance of preexisting nevi
Glucose Intolerance and Diabetes Mellitus: Treatment with somatropin may decrease insulin sensitivity, particularly at higher doses. New onset type 2 diabetes has been reported. Monitor glucose levels in all patients, especially in those with existing diabetes mellitus or with risk factors for diabetes mellitus, such as obesity, Turner syndrome, or a family history of diabetes mellitus. The doses of antidiabetic agents may require adjustment when Sogroya^® is initiated
Intracranial Hypertension: Has been reported usually within 8 weeks of treatment initiation. Perform fundoscopic examination prior to initiation of treatment and periodically thereafter. If papilledema is identified, evaluate the etiology, and treat the underlying cause before initiating Sogroya^®. If papilledema is observed, stop treatment. If intracranial hypertension is confirmed, Sogroya^® can be restarted at a lower dose after intracranial hypertension signs and symptoms have resolved
Fluid Retention: Was observed during Sogroya^® therapy. Clinical manifestations of fluid retention (e.g. edema and nerve compression syndromes, including carpal tunnel syndrome/paresthesia) are usually transient and dose dependent
Hypoadrenalism: Patients receiving somatropin therapy who have or are at risk for corticotropin deficiency may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of Sogroya^®. Monitor patients with known hypoadrenalism for reduced serum cortisol levels and/or need for glucocorticoid dose increases
Hypothyroidism: Undiagnosed/untreated hypothyroidism may prevent an optimal response to Sogroya^®. Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of Sogroya^®
Slipped Capital Femoral Epiphysis in Pediatric Patients: Slipped capital femoral epiphysis may occur more frequently in patients undergoing rapid growth. Slipped capital femoral epiphysis may lead to osteonecrosis. Cases of slipped capital femoral epiphysis with or without osteonecrosis have been reported in pediatric patients with short stature receiving somatropin. Evaluate pediatric patients receiving Sogroya® with the onset of a limp or complaints of persistent hip or knee pain for slipped capital femoral epiphysis and osteonecrosis and manage accordingly
Progression of Preexisting Scoliosis in Pediatric Patients: Monitor patients with a history of scoliosis for disease progression
Pancreatitis: Cases of pancreatitis have been reported in patients receiving somatropin. The risk may be greater in pediatric patients compared to adults. Consider pancreatitis in patients with persistent severe abdominal pain
Lipohypertrophy/Lipoatrophy: May occur if Sogroya^® is administered at the same site over a long period of time. Rotate injection sites to reduce this risk
Sudden Death in Pediatric Patients with Prader-Willi Syndrome: There have been reports of fatalities after initiating therapy with somatropin in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk than females. Sogroya^® is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome
Laboratory Tests: Serum levels of inorganic phosphorus and alkaline phosphatase have increased after Sogroya^® therapy. Serum levels of parathyroid hormone may increase with somatropin treatment

Adverse Reactions

Common adverse reactions in pediatric patients treated with Sogroya^® include: cough, diarrhea, ear infection, headache, injection site reaction, nasopharyngitis, pain in extremity, pyrexia, respiratory tract infection, and vomiting
Adult patients with GHD: Adverse reactions reported in >2% of patients are: back pain, arthralgia, dyspepsia, sleep disorder, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, blood creatine phosphokinase increase, weight increase, anemia

Drug Interactions

Glucocorticoids: Patients treated with glucocorticoid for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of Sogroya^®
Cytochrome P450-Metabolized Drugs: Sogroya^® may alter the clearance. Monitor carefully if used with Sogroya^®
Oral Estrogen: Patients receiving oral estrogen replacement may require higher Sogroya^® dosages
Insulin and/or Other Antihyperglycemic Agents: Dose adjustment of insulin and/or antihyperglycemic agent may be required for patients with diabetes mellitus

Please click here for Sogroya^® Prescribing Information.

Indications and Usage

Sogroya^® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg is indicated for the:

treatment of pediatric patients aged 2.5 years and older with:
- Growth failure due to inadequate secretion of endogenous growth hormone (GH)
- Short stature born Small for Gestational Age (SGA) and with no catch-up growth by 2 years of age
- Growth failure associated with Noonan Syndrome (NS)
- Idiopathic Short Stature (ISS)
replacement of endogenous GH in adults with growth hormone deficiency (GHD)

Indications and Usage

Sogroya^® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg is indicated for the:

treatment of pediatric patients aged 2.5 years and older with:
- Growth failure due to inadequate secretion of endogenous growth hormone (GH)
- Short stature born Small for Gestational Age (SGA) and with no catch-up growth by 2 years of age
- Growth failure associated with Noonan Syndrome (NS)
- Idiopathic Short Stature (ISS)
replacement of endogenous GH in adults with growth hormone deficiency (GHD)

Important Safety Information for Sogroya^®

Contraindications

Sogroya^® is contraindicated in patients with:

acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure because of the risk of increased mortality with use of Sogroya^®
hypersensitivity to Sogroya^® or any of its excipients. Systemic hypersensitivity reactions have been reported postmarketing with somatropin
pediatric patients with closed epiphyses
active malignancy
active proliferative or severe non-proliferative diabetic retinopathy
pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to risk of sudden death

Warnings & Precautions

Increased Mortality in Patients with Acute Critical Illness: Increased mortality has been reported after treatment with somatropin in patients with acute critical illness due to complications following open-heart surgery, abdominal surgery, multiple accidental trauma, and in patients with acute respiratory failure
Severe Hypersensitivity: Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported postmarketing with use of somatropin. Inform patients and/or caregivers that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs
Increased Risk of Neoplasms: There is an increased risk of malignancy progression with somatropin in patients with active malignancy. Any preexisting malignancy should be inactive, and its treatment complete prior to instituting Sogroya^®. In childhood cancer survivors treated with radiation to the brain/head for their first neoplasm who developed subsequent GHD and were treated with somatropin, an increased risk of a second neoplasm has been reported. Monitor patients with a history of GHD secondary to an intracranial neoplasm for progression or recurrence of the tumor. Children with certain rare genetic causes of short stature have an increased risk of developing malignancies and should be carefully monitored for development of neoplasms. Monitor patients for increased growth or potential malignant changes of preexisting nevi. Advise patients/caregivers to report changes in the appearance of preexisting nevi
Glucose Intolerance and Diabetes Mellitus: Treatment with somatropin may decrease insulin sensitivity, particularly at higher doses. New onset type 2 diabetes has been reported. Monitor glucose levels in all patients, especially in those with existing diabetes mellitus or with risk factors for diabetes mellitus, such as obesity, Turner syndrome, or a family history of diabetes mellitus. The doses of antidiabetic agents may require adjustment when Sogroya^® is initiated
Intracranial Hypertension: Has been reported usually within 8 weeks of treatment initiation. Perform fundoscopic examination prior to initiation of treatment and periodically thereafter. If papilledema is identified, evaluate the etiology, and treat the underlying cause before initiating Sogroya^®. If papilledema is observed, stop treatment. If intracranial hypertension is confirmed, Sogroya^® can be restarted at a lower dose after intracranial hypertension signs and symptoms have resolved
Fluid Retention: Was observed during Sogroya^® therapy. Clinical manifestations of fluid retention (e.g. edema and nerve compression syndromes, including carpal tunnel syndrome/paresthesia) are usually transient and dose dependent
Hypoadrenalism: Patients receiving somatropin therapy who have or are at risk for corticotropin deficiency may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of Sogroya^®. Monitor patients with known hypoadrenalism for reduced serum cortisol levels and/or need for glucocorticoid dose increases
Hypothyroidism: Undiagnosed/untreated hypothyroidism may prevent an optimal response to Sogroya^®. Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of Sogroya^®
Slipped Capital Femoral Epiphysis in Pediatric Patients: Slipped capital femoral epiphysis may occur more frequently in patients undergoing rapid growth. Slipped capital femoral epiphysis may lead to osteonecrosis. Cases of slipped capital femoral epiphysis with or without osteonecrosis have been reported in pediatric patients with short stature receiving somatropin. Evaluate pediatric patients receiving Sogroya® with the onset of a limp or complaints of persistent hip or knee pain for slipped capital femoral epiphysis and osteonecrosis and manage accordingly
Progression of Preexisting Scoliosis in Pediatric Patients: Monitor patients with a history of scoliosis for disease progression
Pancreatitis: Cases of pancreatitis have been reported in patients receiving somatropin. The risk may be greater in pediatric patients compared to adults. Consider pancreatitis in patients with persistent severe abdominal pain
Lipohypertrophy/Lipoatrophy: May occur if Sogroya^® is administered at the same site over a long period of time. Rotate injection sites to reduce this risk
Sudden Death in Pediatric Patients with Prader-Willi Syndrome: There have been reports of fatalities after initiating therapy with somatropin in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk than females. Sogroya^® is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome
Laboratory Tests: Serum levels of inorganic phosphorus and alkaline phosphatase have increased after Sogroya^® therapy. Serum levels of parathyroid hormone may increase with somatropin treatment

Adverse Reactions

Common adverse reactions in pediatric patients treated with Sogroya^® include: cough, diarrhea, ear infection, headache, injection site reaction, nasopharyngitis, pain in extremity, pyrexia, respiratory tract infection, and vomiting
Adult patients with GHD: Adverse reactions reported in >2% of patients are: back pain, arthralgia, dyspepsia, sleep disorder, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, blood creatine phosphokinase increase, weight increase, anemia

Drug Interactions

Glucocorticoids: Patients treated with glucocorticoid for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of Sogroya^®
Cytochrome P450-Metabolized Drugs: Sogroya^® may alter the clearance. Monitor carefully if used with Sogroya^®
Oral Estrogen: Patients receiving oral estrogen replacement may require higher Sogroya^® dosages
Insulin and/or Other Antihyperglycemic Agents: Dose adjustment of insulin and/or antihyperglycemic agent may be required for patients with diabetes mellitus

Please click here for Sogroya^® Prescribing Information.

References:

Kapoor RR, Burke SA, Sparrow SE, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child.2008;93(2):147-148. doi:10.1136/adc.2006.114249
Iglay K, Cao X, Mavros P, Joshi K, Yu S, Tuncell K. Systematic literature review and meta-analysis of medication adherence with once-weekly versus once-daily therapy. Clin Ther. 2015;37(8):1813-1821.e1. doi:10.1016/j.clinthera.2015.05.505
Maniatis A, Cutfield W, Dattani M, et al. Long-acting growth hormone therapy in pediatric growth hormone deficiency: a consensus statement. J Clin Endocrinol Metab. Published online December 3, 2024. doi:10.1210/clinem/dgae834
Christiansen JS, Backeljauw PF, Bidlingmaier M, et al. Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol. 2016;174(6):C1–C8. doi:10.1530/EJE-16-0111
Graham S, Weinman J, Auyeung V. Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: a systematic review. Horm Res Paediatr. 2018;90(4):221-227. doi:10.1159/000493211
Bagnasco F, Di Iorgi N, Roveda A, Gallizia A, Haupt R, Maghnie M; Adherence Investigators Group. Prevalence and correlates of adherence in children and adolescents treated with growth hormone: a multicenter Italian study. Endocr Pract. 2017;23(8):929-941. doi:10.4158/EP171786.OR
Mameli C, Orso M, Calcaterra V, et al. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: a systematic review and meta-analysis. Pharmacol Res. 2023;193:106805. doi:10.1016/j.phrs/2023.106805
Loftus J, Chen Y, Alvir JMJ, et al. Suboptimal adherence to daily growth hormone in a US real-world study: an unmet need in the treatment of pediatric growth hormone deficiency. Curr Med Res Opin. 2021;37(12):2141-2150. doi: 10.1080/03007995.2021.1982682
National Organization for Rare Disorders (NORD). Growth hormone deficiency. Updated 2016. Accessed November 17, 2022. https://rarediseases.org/rare-diseases/growth-hormone- deficiency
Yuen KCJ, Beverly MKB, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract. 2019;25(11):1191-1232.
Ranke MB. Treatment of children and adolescents with idiopathic short stature. Nat Rev Endocrinol. 2013;9(6):325-334. doi: 10.1038/nrendo.2013.71
Polak M, Blair J, Kotnik P, Pournara E, Pedersen BT, Rohrer TR. Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet® International Outcome Study. Eur J Endocrinol. 2017;177(5):421-429. doi:10.1530/EJE-16-1024
Pedicelli S, Peschiaroli E, Violi E, Cianfarani S. Controversies in the definition and treatment of idiopathic short stature (ISS). J Clin Res Pediatr Endocrinol. 2009;1(3):105-115. doi:10.4008/jcrpe.v1i3.53
Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008;93(11):4210-4217. doi: 10.1210/jc.2008-0509
Wu W, Li N, Wang T, Luo X. Real-life growth hormone treatment patterns in children from China: a report from two databases. Adv Ther. 2025;42(7):3562-3575. doi:10.1007/s12325-025-03204-9
Ben-Ari T, Chodick G, Shalev V, Goldstein D, Gomez R, Landau Z. Real-world treatment patterns and outcomes of growth hormone treatment among children in Israel over the past decade (2004- 2015). Front Pediatr. 2021;9:711979. doi: 10.3389/fped.2021.711979
Salles J-P, Coutant R, Leheup B, Nicolina M, Hacques E, Villette B. Small for gestational age patients with premature treatment discontinuation: their journey in French, real-life settings. Poster presented at: 57th Meeting of the European Society for Paediatric Endocrinology; September 27-29, 2018; Athens, Greece. Poster P3-P200.
De Pedro S, Murillo M, Salinas I, et al. Variability in adherence to rhGH treatment: Socioeconomic causes and effect on children's growth. Growth Harm IGF Res. 2015;25(6):280-283. doi:10.1016/j.ghir.2015.12.002
Ferrigno R, Savanelli MC, Cioffi D, Pellino V, Klain A. Auxological and metabolic effects of long-term treatment with recombinant growth hormone in children born small for gestational age: a retrospective study. Endocrine. 2024;84(1):213-222. doi:10.1007/s12020-023-03665-4
Jung H, Rosilio M, Blum WF, Drop SL. Growth hormone treatment for short stature in children born small for gestational age. Adv Ther. 2008;25(10):951-978. doi:10.1007/s12325-008-0101-3
Bellido-González M, Robles-Ortega H, Castelar-Ríos MJ, e t al. Psychological distress and resilience of mothers and fathers with respect to the neurobehavioral performance of small-for-gestational-age newborns. Health Qual Life Outcomes. 2019;17(1):54. doi:10.1186/s12955-019-1119-8
Seo GH, Yoo HW. Growth hormone therapy in patients with Noonan syndrome. Ann Pediatr Endocrinol Metab. 2018;23(4):176-181. doi:10.6065/apem.2018.23.4.176
Kappelgaard AM, Laursen T. The benefits of growth hormone therapy in patients with Turner syndrome, Noonan syndrome and children born small for gestational age. Growth Hormone & IGF Research. 2011;21 (6):253-262.
Stagi S, Cappa M, Gagliardi MG, Tartaglia M, Maghnie M, Italian Multidisciplinary Noonan Syndrome Working Group. Multidisciplinary Treatment of Patients With Noonan Syndrome: A Consensus Statement. JAMA Netw Open.2025;8(10):e2537603. doi:10.1001 /jamanetworkopen.2025.37603
Rohrer TR, Abuzzahab J, Backeljauw P, et al. Long-term effectiveness and safety of childhood growth hormone treatment in Noonan syndrome. Horm Res Paediatr. 2020.

Explore Therapeutic Areas

Explore the Hub

Explore Therapeutic Areas

Explore Current Therapy Area

Explore Current Therapy Area

Claim your personalized professional hub

Personalize your novoMEDLINK™ experience

WHY A ONCE-WEEKLY THERAPY?

WHY A ONCE-WEEKLY THERAPY?

Missing multiple daily injections per week may substantially impact growth outcomes1

Daily injections may present obstacles for patients and their caregivers

Pediatric GHD

1 DAY

52 DAYS

~1 YEAR

Adult GHD

GHD occurs in adults and has associated symptoms and conditions

Symptoms and associated conditions of adult GHD include9:

Symptoms and associated conditions of adult GHD include9:

Management of adult GHD

Treatment options4,10

How might treatment adherence affect pediatric patients with other specific growth-related conditions?

Idiopathic Short Stature (ISS)

Early initiation and adherence to GH therapy may lead to improved growth outcomes in pediatric patients with ISS4,11-14

Small for Gestational Age (SGA) with no catch-up growth by 2 years of age

For children born SGA who are on GH therapy, treatment fatigue and poor adherence may lead to reduced growth outcomes17,18

Noonan Syndrome (NS)

Children with NS face a complex treatment burden, which may impact medication adherence22,23

Discover the pen

Discover the pen

How does it work?

How does it work?

Important Safety Information for Sogroya®

Contraindications

Warnings & Precautions

Adverse Reactions

Drug Interactions

Indications and Usage

Indications and Usage

Important Safety Information for Sogroya®

Contraindications

Warnings & Precautions

Adverse Reactions

Drug Interactions

Indications and Usage

Indications and Usage

Important Safety Information for Sogroya®

Contraindications

Important Safety Information for Sogroya®

Contraindications

Warnings & Precautions

Adverse Reactions

Drug Interactions

Important Safety Information for Sogroya®

Contraindications

Warnings & Precautions

Adverse Reactions

Drug Interactions

Indications and Usage

Indications and Usage

Important Safety Information for Sogroya®

Contraindications

Warnings & Precautions

Adverse Reactions

Drug Interactions

What can we help you do today?

Claim your personalized
professional hub

Missing multiple daily injections per week may substantially impact growth outcomes¹

Symptoms and associated conditions of adult GHD include⁹:

Symptoms and associated conditions of adult GHD include⁹:

Treatment options^4,10

Early initiation and adherence to GH therapy may lead to improved growth outcomes in pediatric patients with ISS^4,11-14

For children born SGA who are on GH therapy, treatment fatigue and poor adherence may lead to reduced growth outcomes^17,18

Children with NS face a complex treatment burden, which may impact medication adherence^22,23

Important Safety Information for Sogroya^®

Important Safety Information for Sogroya^®

Important Safety Information for Sogroya^®

Important Safety Information for Sogroya^®

Important Safety Information for Sogroya^®

Important Safety Information for Sogroya^®